Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 3/17/20 (What's New)

Summary

  • The use of dual atazanavir/ritonavir plus lamivudine therapy for maintenance of viral suppression has been evaluated in several trials
    • SALT: dual boosted atazanavir plus lamivudine was noninferior to triple therapy of boosted atazanavir plus 2 NRTIs for maintenance of virologic suppression through 48 weeks[Perez-Molina 2015]
      • Approximately one half of patients in both arms had grade 3/4 hyperbilirubinemia

Action required

Keywords: Switch Strategies

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.